Recent 8-K filings for ANRO

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 13, 2026 11:04 UTC earnings item 2.02item 9.01

  Alto Neuroscience Q1 net loss $26.2M; initiates Phase 2b trial for ALTO-207 in TRD

source · ANRO on sec.gov